Mike Nedelcovych surveys the GLP-1 space after the FDA declared the shortage over, boosting makers like NVO and LLY and hurting compounding pharmacies like HIMS, who will stop offering the drugs. He thinks GLP-1s have the “wind at their back,” but notes that the government may be cracking down on Medicare/Medicaid use of the drugs. However, he says that Medicare expansion would be “icing on the cake.”